Kepler Capital analyst David Evans maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) on October 30 and set a price target of p1,500.00. The company’s shares closed yesterday ...
The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...
limited upside in pipeline catalysts and 2025 estimates “makes it increasingly challenging for us to recommend that investors put new money to work in GSK until pipeline visibility improves ...
To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Sales of GSK’s top-selling vaccines fell sharply during the third quarter amid lower demand ...
The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to ... planning launches for five major new product approval opportunities next ...
Moderna to defend against GSK's claims, spokesperson says GSK seeks unspecified monetary damages from Moderna A spokesperson for Massachusetts-based Moderna said the company was aware of the ...
London-based GSK is crossing the pond to form a new lung disease research collaboration with Boston scientists. The Big Pharma is joining forces with researchers from the Center for Regenerative ...
On Wednesday, the FDA accepted GSK plc’s (NYSE:GSK) marketing application seeking approval for gepotidacin, an investigational, oral antibiotic for adult and adolescent females with ...
GlaxoSmithKline is under pressure from shareholders ... The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement ...
In May 2024, GSK announced positive headline results from the phase III clinical trials SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of depemokimab versus placebo in adults and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback